IGC Pharma Announces First Patient Dosed at ClinCloud in Phase 2 Trial on Agitation in Alzheimer’s Disease
Unveiling Hope – A Breakthrough in Alzheimer’s Treatment
Trial to investigate the efficacy of IGC-AD1 on agitation in Alzheimer’s Disease impacting 40-80% of patients
POTOMAC, MD., January 15, 2024 — IGC Pharma, Inc (NYSE American: IGC) (“IGC” or the “Company”), today announced that the first patient was dosed at the ClinCloud clinical research facility in Florida as part of the Company’s ongoing Phase 2 trial.
IGC Pharma is currently conducting a Phase 2 trial with IGC-AD1, a partial CB1r agonist with anti-neuroinflammatory properties, and an inflammasome inhibitor to treat agitation in dementia from Alzheimer’s. Neuroinflammation, neurotransmitter imbalance, loss of CB1r, and inflammasome-3 have been implicated in agitation/aggression.
Today marks a significant stride in the pursuit of a breakthrough therapy for agitation in Alzheimer’s disease as IGC Pharma proudly announces the initiation of its Phase 2 trial, with the first patient dosed at ClinCloud in Florida.
Agitation in Alzheimer’s is a challenging aspect affecting over 80% of patients and causing distress to both patients and their caregivers. IGC-AD1, a partial CB1r agonist with anti-neuroinflammatory properties, and an inflammasome inhibitor, is at the forefront of innovative treatment strategies.
Jessica Branning, Founder at ClinCloud, commented, “Treatment options targeting agitation in Alzheimer’s disease are currently limited. This Phase 2 clinical trial aligns with ClinCloud’s mission to transform healthcare with continuous improvements and revolutionary breakthroughs. It’s more important than ever to identify treatments for neurodegenerative conditions.”
Ram Mukunda, CEO of IGC Pharma stated, “We are excited to announce this important milestone in the Phase 2 trial of IGC-AD1. This strategic move amplifies our reach and strengthens the depth of our data collection, marking a critical phase in our pursuit of a breakthrough therapy for agitation in Alzheimer’s disease.”
IGC Pharma has 12 other sites under contract and is on target to roll out additional sites in the U.S. and in Canada to increase population diversity and promote the inclusion of underrepresented populations. The trial will enroll 146 patients with one half, the treated group, receiving IGC-AD1, and the other half, the control group, receiving a placebo.
About ClinCloud
ClinCloud Clinical Research (www.clincloudresearch.com) has 2 centers located in Melbourne and Maitland, Florida, with active clinical studies in Alzheimer’s disease, and other diseases.
